ライフサイエンスコーパス: neutral endopeptidase

1 rphin A was prevented by aminopeptidases and neutral endopeptidase.

2 he first evidence that keratinocytes produce neutral endopeptidase.

3 idase A and B, chymotrypsin, subtilisin, and neutral endopeptidase.

4 muscle is due to interaction with the enzyme neutral endopeptidase.

5 oup, comprise the M13 subfamily of mammalian neutral endopeptidases.

6 shares homology to members of the family of neutral endopeptidases.

7 e molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE.

8 The cell surface zinc metalloproteinase CD10/neutral endopeptidase 24.11 ([NEP] neprilysin) functions

9 eptidases, namely aminopeptidase N (APN) and neutral endopeptidase 24.11 (NEP 24.11).

10 s, angiotensin I-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) are the major kininase

11 plays high amino acid sequence identity with neutral endopeptidase 24.11 (NEP) especially at the cata

12 ration of action in vivo, the dual ECE-1 and neutral endopeptidase 24.11 (NEP) inhibitor, CGS 26303,

13 zofused macrocyclic lactams were designed as neutral endopeptidase 24.11 (NEP) inhibitors.

14 Neutral endopeptidase 24.11 (NEP) is a cell surface pept

15 Neutral endopeptidase 24.11 (NEP) is a cell-surface enzy

16 Neutral endopeptidase 24.11 (NEP) is a cell-surface pept

17 Neutral endopeptidase 24.11 (NEP) is a metalloprotease t

18 CD10/neutral endopeptidase 24.11 (NEP) regulates peptidemedia

19 n the crystal structure of the ectodomain of neutral endopeptidase 24.11 (NEP).

20 Neutral endopeptidase 24.11 (NEP, CD10) is a cell-surfac

21 ty and a small, but significant, increase in neutral endopeptidase 24.11 activity in the cheek pouch,

22 Because the enzyme neutral endopeptidase 24.11 is an important kininase in

23 Kell has closest homology with neutral endopeptidase 24.11, endothelin converting enzym

24 thway is under the control of three enzymes: neutral endopeptidases 24.11 (neprilysin) and 24.15 and

25 Adjacent skin had a median neutral endopeptidase activity 4.34 x higher (p<0.001) t

26 This elevated neutral endopeptidase activity in the skin and chronic u

27 The median neutral endopeptidase activity of proximal skin was 2.90

28 The median neutral endopeptidase activity of the ulcer margin was 1

29 The neutral endopeptidase activity was approximately 7-fold

30 Neutral endopeptidase activity was measured using a fluo

31 scular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme

32 ANP and fsANP are preferentially degraded by neutral endopeptidase and serine peptidases, respectivel

33 We investigated whether neutral endopeptidase could inhibit angiogenesis in vivo

34 The cell surface enzyme, neutral endopeptidase, degrades substance P, thereby reg

35 in metabolism is dependent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and amin

36 lts from this investigation demonstrate that neutral endopeptidase (EC 3.4.24.11) is one of the major

37 terized using a monoclonal antibody to human neutral endopeptidase, EC 3.4.24.11.

38 carotid body is structurally similar to the neutral endopeptidase, EC 3.4.24.11.

39 We hypothesized that neutral endopeptidase enzymatic activity is increased in

40 Neutral endopeptidase enzymatic bioactivity was demonstr

41 We compared cutaneous neutral endopeptidase expression and enzymatic activity

42 he objectives of this study were to evaluate neutral endopeptidase expression in wounded and unwounde

43 d on Xp22.1, is homologous to members of the neutral endopeptidase family.

44 The distribution of neutral endopeptidase in normal skin and wounded human s

45 vascular endothelial cells demonstrated that neutral endopeptidase inhibition significantly enhanced

46 Three strategies were tested: inhibition of neutral endopeptidase, inhibition of aldose reductase pl

47 se severity when given in combination with a neutral endopeptidase inhibitor (enhances endogenous nat

48 -135 and Gly-136, which was inhibited by the neutral endopeptidase inhibitor CGS24592 and heparin.

49 Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we

50 ibitor captopril, to -6.33 +/- 0.19 with the neutral endopeptidase inhibitor phosphoramidon and to -7

51 eletal muscle, we examined the effect of the neutral endopeptidase inhibitor phosphoramidon on the bi

52 ramiprilat (10(-4) mol/L, -21+/-2%), and the neutral endopeptidase inhibitor thiorphan (10(-4) mol/L,

53 (n = 10), phosphoramidon (a combined ECE and neutral endopeptidase inhibitor) and BQ-123 (an ETA rece

54 2), respectively, and thiorphan (a selective neutral endopeptidase inhibitor) reduced FBF by 15 +/- 5

55 n=87) versus the vasopeptidase (dual ACE and neutral endopeptidase) inhibitor omapatrilat 80 mg daily

56 Clinical studies of neutral endopeptidase inhibitors and angiotensin II rece

57 Neutral endopeptidase is a cell surface enzyme that degr

58 the matrix metalloproteinase (MMP) family of neutral endopeptidases, is expressed in the skeleton dur

59 Neutral endopeptidase may terminate the proinflammatory

60 Neutral endopeptidase mRNA was detected in normal skin a

61 es like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP) 24.11 severely compromises i

62 y was to establish the effect of oleacein on neutral endopeptidase (NEP) activity and other functions

63 both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) activity in vitro were obser

64 fections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth fact

65 gest that insulin-degrading enzyme (IDE) and neutral endopeptidase (NEP) are involved in the extracel

66 s of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo.

67 Neutral endopeptidase (NEP) degrades vasoactive peptides

68 f the natriuretic peptide (NP) receptors and neutral endopeptidase (NEP) in mediating and modulating

69 The cell-surface enzyme neutral endopeptidase (NEP) inactivates both peptides.

70 e herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential tre

71 Neutral endopeptidase (NEP) is a cell surface enzyme fou

72 Neutral endopeptidase (NEP) is a cell-surface enzyme tha

73 Neutral endopeptidase (NEP) is a genetically distinct me

74 Neutral endopeptidase (NEP) is expressed on normal prost

75 as the expression of the SP-degrading enzyme neutral endopeptidase (NEP) is increased, compared to co

76 the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits

77 Neutral endopeptidase (NEP) uses SP as a substrate to pr

78 ndrogen-sensitive LNCaP cells, which express neutral endopeptidase (NEP), but not in androgen-indepen

79 nt vasoconstrictor into its active form, and neutral endopeptidase (NEP), which is involved in termin

80 ors indicated that the previously identified neutral endopeptidase (NEP)-like activity is the major p

81 nstrated substrate preference for Ang I, was neutral endopeptidase (NEP)-like.

82 and absence of long-term oral inhibition of neutral endopeptidase (NEP).

83 kephalin, the natural substrate of the human neutral endopeptidase (NEP).

84 both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).

85 nhibitors of the two zinc metallopeptidases, neutral endopeptidase (NEP, EC 3.4.24.11) and angiotensi

86 Neutral endopeptidase (NEP; CALLA, CD10, EC 3.4.24.11) i

87 ed plasma half-life due to its resistance to neutral-endopeptidase (NEP) digestion.

88 ich blocks angiotensin converting enzyme and neutral endopeptidase, on these endpoints.

89 common acute lymphoblastic leukemia antigen, neutral endopeptidase, or enkephalinase, can be used as

90 dipeptidyl carboxypeptidase (captopril), and neutral endopeptidase (phosphoramidon) dramatically incr

91 By 28 d post wounding neutral endopeptidase staining again was detected only i

92 me required for kidney membranes or purified neutral endopeptidase to abolish ANP-dependent activatio

93 Neutral endopeptidase was localized by immunohistochemis

94 Staining for neutral endopeptidase was noted in the wound bed 6 h aft

95 Neutral endopeptidase was strikingly localized in normal

96 otein levels of the enzyme that degrades SP, neutral endopeptidase, were increased.

97 Incubation with neutral endopeptidase, which degrades bombesin, or bombe

98 eptidase inhibitors inhibit ACE activity and neutral endopeptidase, which degrades natriuretic peptid

99 bits angiotensin-converting enzyme (ACE) and neutral endopeptidase, which degrades vasodilatory facto

100 at released opioids are primarily cleaved by neutral endopeptidase, with a lesser involvement of amin